The gibbon ape leukaemia virus envelope fusogenic membrane glycoprotein (GALV FMG) is a highly potent cytotoxic gene with great potential for use in cancer gene therapy. Here, we show that production of a VSV-G pseudotyped lentiviral vector expressing GALV FMG reconciles the requirements of viral production with the cytotoxic effects of GALV in human cells and has high titres on both dividing and quiescent tumour cells. Direct intratumoral injection of these stocks eradicated progressively growing human tumour xen-
Introduction
Effective gene therapy for cancer requires the harnessing of the potency of therapeutic genes with the ability to generate high efficiency vectors with which to deliver them. 1 We have recently shown that a novel class of genes, the fusogenic membrane glycoproteins (FMG), are extremely potent at killing tumour cells in vitro. 2 We have used a C-terminally truncated form of the gibbon ape leukaemia virus envelope glycoprotein (GALV) as an example of one such FMG. 2, 3 The GALV FMG lacks the 16 amino acid R-peptide of the wild-type protein, which normally serves to restrict fusion of the envelope until it is cleaved during viral infection. 4 This alteration in GALV FMG renders the protein constitutively highly fusogenic to human cells (which express the Pit-1 receptor for GALV). Transfection of the GALV FMG into a range of human tumour cells kills them, through a process of syncytial formation. In addition, the bystander killing effect is at least one log higher using FMG than the suicide genes HSVtk or cytosine deaminase. Syncytial killing is also highly immunostimulatory, through the expression of immunogenic viral antigens coupled with induction of heat shock proteins associated with the mechanisms of cell killing. 2, 5, 6 To exploit the therapeutic potential of FMG, we have now investigated the optimal ways to package the appropriate cDNAs into viral vectors to achieve high-level in vivo delivery to tumours.
Recently, the use of adenoviral vectors for gene delivery to tumour cells has become increasingly popular, relative to other vector types. This is principally because ografts. The potent bystander effect of the FMG transgene is a major contributor to the success of this approach but immunological activation may also be a factor. To our knowledge, this is the first demonstration in vivo of the potential both of FMG and lentiviral vectors for cancer gene therapy and highlights the importance of exploring different vector systems to complement the biological properties of the therapeutic transgene. Gene Therapy (2000) 7, 1656-1663.
of the higher titres that can be achieved 7 and partly because the results of early clinical trials with C-type retroviruses have shown disappointingly low levels of transduction. 8 Nonetheless, several factors suggest that retroviral vectors may yet prove to be of clinical value in the context of tumour therapy. There is a breadth of knowledge on how to target the infection and expression of retroviral vectors, 9 they are relatively lacking in immunogenicity and there is extensive knowledge of vector production and safety issues with these vectors. Moreover, the development of the lentiviral vectors has opened many new potential opportunities, [10] [11] [12] [13] which, as yet, have not been explored for cancer gene therapy. In this respect, the ability of lentiviral vectors to infect both dividing and nondividing cells in a tumour may overcome some of the barriers to efficient gene delivery to human tumours experienced with C-type retroviral vectors, 14 where only a relatively small proportion of tumour cells may be cycling at any given time. 8 In practice, multiple considerations affect the choice of vector to be used for a specific therapeutic gene. For example, genes which are directly cytotoxic -such as the GALV FMG -as opposed to those activated by administration of a prodrug 15 or which are immunostimulatory, 16 make high-titre viral production problematic. In this respect, generation of high-titre adenoviral vectors encoding the GALV FMG is difficult due to the rapid fusion of the producer cells before viral packaging, morphogenesis and release is possible. Whilst we are exploring mechanisms to overcome some of these problems, 17, 18 it may be that other vector systems may prove to be superior for the delivery of FMG to tumours in vivo.
For these reasons, we have explored the value of retroviral vectors, including lentiviruses, to deliver the GALV FMG for antitumour therapies in vivo. Here, we describe the issues involved in selecting the most appropriate delivery system for the highly cytotoxic GALV FMG, which is itself a truncated form of a C-type retroviral envelope. We show that lentiviral vector packaging and production are well suited to this context, being consistent with both the cytotoxicity of the transgene to human cells and the time-frame required for generation of viral particles. Finally, we demonstrate, for the first time to our knowledge, the use of lentiviral vectors to eradicate established and actively growing human tumour xenografts in nude mice, highlighting the potential of this class of vector for cancer gene therapy.
Results

Retroviral vectors expressing the GALV FMG
We constructed two retroviral plasmids capable of expressing the GALV FMG. The first, pBabe-GALV, is an Mo-MLV-derived C-type retroviral vector, of the type that we have previously used for the high efficiency of transfer of therapeutic genes to tumour cells. 19, 20 In this vector, the GALV FMG cDNA is expressed from the Mo-MLV LTR in infected cells. The second, Lenti-GALV, was constructed from an HIV-based self inactivating vector in which the 3ЈLTR is transcriptionally disabled. Therefore, in this vector, the GALV FMG cDNA is expressed from the CMV promoter. We have previously shown that there is a low threshold level of expression required for GALVmediated toxicity to target cells (Emiliusen et al, manuscript in preparation). To ensure that the strengths of the different promoters would not adversely affect our subsequent evaluation of these two vectors, 10 6 target cells were transfected with 1 g of each plasmid. Both the pBabe-GALV and Lenti-GALV plasmids were able to kill over 90% of target cells through syncytial production ( Figure 1 ). Hence, although the Mo-MLV LTR and the CMV promoters are unlikely to have the same strength in target cells, the low threshold level of expression which is required for GALV-mediated toxicity means that they Gene Therapy can be compared on a similar level in subsequent infection assays.
Packaging of C-type and lentiviral vectors expressing GALV FMG We compared the ability of different packaging cell lines, and protocols, to generate infectious virus stocks between the C-type and lentiviral plasmids within the specific context of the GALV FMG. Therefore, we investigated whether a murine packaging cell line, which will not be fused by GALV FMG because mouse cells do not express the Pit-1 receptor, could be generated to produce hightitre, stable producer lines (which would, however, produce virus sensitive to inactivation by human complement). In addition, previous reports have shown that co-expression of two different C-type envelopes can co-operate both structurally and functionally. 21 Therefore, pBabe-GALV was transfected into the third generation, murine packaging line GP+envAM12 22 and stable puromycin-resistant colonies were generated. However, from all of the clones assayed, the titres were consistently low (the best being Ͻ10 2 puro r colony-forming units/ml on NIH3T3 cells) ( Table 1) . Since GP+envAM12 cells stably produce the MLV-A 4070A envelope protein, we are investigating whether co-expression of the truncated GALV and the 4070A envelope lead to mixed heterotrimeric envelope complexes which are not competent for infection of target cells, despite the demonstration that the Mo-MLV and 10A1 MLV envelopes could functionally interact. 21 The FLY-13 packaging cell line also stably expresses the 4070A envelope but generates C-type particles which will not be sensitive to human complement inactivation. 23 Transfection of the human packaging line FLY-13 led to the generation of few stable colonies, none of which generated detectable virus since the expression of the GALV cDNA is incompatible with longterm survival of human cell lines. Titres from FLY-13 cells transiently transfected with pBabe-GALV were also consistently low, perhaps for the same reason of envelope protein mixing that GP+envAM12 cells were unable to generate high titres (Table 1) . Therefore, to avoid envelope mixing, pBabe-GALV was transfected into the 293Int cell line. This human line stably expresses the Mo-MLV gag and pol genes but no envelope to interfere with the co-expressed GALV FMG. In the absence of any additionally supplied envelope, the truncated GALV FMG was able to pseudotype the pBabe-GALV core particles but only at low efficiency (Table 1) . This low efficiency of pseudotyping by the truncated GALV envelope is consistent with reports that modifications to the R peptide of C-type envelope genes can significantly reduce their ability to be incorporated into infectious viral particles. 4 Therefore, 293Int cells were cotransfected with pBabe-GALV and the VSV-G envelope, previously shown to pseudotype C-type core particles to high titres 24 and bypassing the possibility of retroviral envelope heterotrimer formation. The virus harvested after 48 h, at which time GALV FMG toxicity was active, gave a best titre of 3 × 10 4 syncytial-forming units (s.f.u.) per millilitre (Table 1) .
To compare this titre with that obtainable with the Lenti-GALV vector, 293T cells were co-transfected with the Lenti-GALV vector as well as the p8.91 vector, 11 which encodes the HIV gag, pol, rev and tat genes. Only low levels of infectious virus were generated, demon- 
The C-type pBabe-GALV or the lentiviral Lenti-GALV vectors were packaged in a variety of ways to demonstrate the most efficient method of generating high-titre, complement-resistant virus, despite the cytotoxicity of the transgene to human cells. Transient titres were determined from virus harvested at 24-72 h after transfection of the producer cells, by which time human cells were being killed by expression of GALV FMG. The best titres obtainable from these experiments are shown.
strating that the C-type truncated GALV could only poorly serve as its own envelope to pseudotype HIV core particles. In contrast, cotransfection of Lenti-GALV, p8.91 and VSV-G generated transient viral titres of, at best, 4 × 10 6 s.f.u./ml (Table 1) , significantly higher than that obtainable with the C-type vector.
GALV-expressing retroviral vectors kill cells with a large bystander effect but only Lenti-vectors infect both dividing and quiescent human tumour cells Virus-mediated delivery of the GALV FMG induces cell killing through induction of syncytia which has a potent bystander killing effect. Delivery of as few as 10 3 viral particles of the Lenti-GALV/VSV-G stock killed in excess of 10 5 tumour cells ( Figure 2 ). Similar levels of bystander killing were observed using the pBabe-GALV vector (data not shown). These results confirm that the bystander killing effect of the GALV FMG is in excess of 1(transduced):100 (nontransduced) cells, much greater than with the HSVtk or cytosine deaminase genes previously used in our laboratory (Ref. 2 and data not shown).
We also determined the titre of the pBabe-GALV/VSVa b c d e f 
Figure 2 GALV-expressing retroviral vectors kill cells with high bystander effects and Lenti-GALV, but not pBabe-GALV, can kill nondividing tumour cells. The bystander killing effect of the FMG-GALV vec
of Lenti-GALV/VSV-G (shown) or pBabe-GALV/VSV-G (not shown), indicating that each infectious particle led to the killing of at least 100 other cells.
G and Lenti-GALV/VSV-G stocks on human tumour cells both in the presence and absence of aphidicolin which blocks cells in the G1-S phase of the cell cycle. Whereas the titre of the Lenti-GALV vector was largely unaltered by preincubation of the HT1080 human tumour line with aphidicolin, the titre of the C-type pBabe-GALV vector was substantially reduced (data not shown). These data confirm that lentiviral vectors can infect target cells irrespective of a block in G1-S phase of the cell cycle. Hence, the effective titre of the viral stock delivered in vivo will be expected to be higher for the Lenti-GALV construct than for the pBabe-GALV vector by not being reduced by nonproductive infections of nondividing cells.
Lentivirus vector expressing GALV can eradicate growth of established tumours in nude mice
Based on the results from Table 1 and Figures 1 and 2 , we investigated whether the Lenti-GALV/VSV-G viral stocks could be effective in an in vivo model of tumour therapy to treat well-established xenografts of HT1080 tumours, when tumour diameters ranged between 0.1 cm and 0.4 cm. Three peritumoral injections of a lentivirus expressing the ␤-galactosidase gene (Lenti-␤-Gal), produced exactly as the Lenti-GALV vector, had a small, but significant, effect on mean tumour size with time compared with tumours injected with PBS (100 l per tumour). However, peritumoral injections of the Lenti-GALV vector (4 × 10 5 virus per tumour per injection) eradicated tumour growth in all animals (10 mice per group), although some animals initially maintained regressing tumours for about a week following the first injection. In the experiment shown, no outgrowths were seen in this group of animals and all 10 animals were tumour free compared with one of 10 in the PBS injected group and two of 10 in the Lenti-␤-Gal injected group at the end of the experiment.
In vivo delivery of Lenti-GALV leads to tumour cell transduction and syncytial killing In subsequent experiments, HT1080 tumours growing in vivo were injected with a single dose of virus or PBS and tumours were excised 48 h later for histology and molecular analysis. Tumours injected with the Lenti-␤-Gal vector were dissected and stained for 4 h in X-gal solution at 37°C. Figure 4a shows that extensive staining was observed (but not in Lenti-GALV or PBS injected tumours). However, the strength of this staining is somewhat deceptive, in that frozen sections of injected tumours suggested that the overall efficiency of gene transfer was only about 1% of cells depending upon the experiment. The discrepancy in the staining between gross tumours and tumour sections could be due to the transfer of free ␤-galactosidase protein into the tumours along with the virus from the producer cells. In addition, it may be that small amounts of transduction lead to expression of ß-Gal protein, which subsequently leaks through the tumour tissue giving an abnormally high apparent level of transduction. Whichever process is responsible, it is important for investigators to be aware of these confounding effects.
To provide indirect evidence that the mechanism of tumor cell killing is through syncytial formation and cell fusion, tumours were recovered from injected mice and re-established in culture. Extensive syncytia were observed following 24 h of growth in vitro in cultures from HT1080-Lenti-GALV injected tumours but not from PBS or Lenti-␤-Gal injected tumours (Figure 4b, c) .
In vivo delivery of Lenti-GALV leads to the induction of immunostimulatory stress responses in tumour cells
We also used injected tumours as a source of cDNA to confirm the expression of the GALV transgene. Figure 5 shows that expression of GALV FMG mRNA could be readily detected in tumours injected with a single dose of the Lenti-GALV vector 48 h after injection. No signal was seen in PBS or ␤-Gal injected tumours. Expression of GAPDH was used as a control to show equal loading. In addition, we used the tumour-derived cDNA to screen for expression of other molecules including mouse and human cytokines, heat shock proteins and other immunostimulatory molecules which may be important in stimulating antitumour effector mechanisms. A summary of the results is shown in Figure 5 . Interestingly, induction of 
Figure 4 Analysis of tumours injected with lentiviral vectors. (a) HT1080 tumours of approximately 0.2-0.3 cm in diameter injected 48 h previously with PBS (lower row) or lentiviral stocks (100 l) (upper row) were excised and dissected before being stained with X-gal solution for 4 h at 37°C. Each well represents a single tumour. Tumours injected with Lenti-␤-Gal virus were extensively stained; however, on sectioning of tumours the efficiency of transduction was no more than 1% of cells depending upon the section inspected. (b) Tumours injected 48 h previously were resected, dissociated and cells were replated overnight in normal growth medium with antibiotics added. Adherent cells were washed gently three times in PBS and examined 12 h later. Large areas of syncytia were observed in cultures recovered from tumours injected with Lenti-GALV virus (b) but not from tumours injected with Lenti-␤-Gal (c).
Figure 5 Killing of tumours in vivo with GALV FMG induces stress response genes in both tumour and host cells. RNA prepared from tumours injected 48 h previously with PBS, Lenti-␤-Gal or Lenti-GALV was reverse transcribed and the cDNA used in PCR analysis for the murine (IL-2, GM-CSF, IFN-␥, hsp70) and human (IFN-␥, hhsc70, hsp70A, MICA, MICB) genes as shown. In addition, PCR was performed for the GALV FMG transgene and for human GAPDH as a control for equal loading of RNA. cDNA recovered from the HT1080 tumours injected with the Lenti-GALV vector were positive for genes indicating a stress response was induced by GALV-mediated killing which also induced a response (mIFN-␥) from murine cells still present in the immunodeficient mice.
expression of three different inducible and constitutive human heat shock proteins was observed (human hhsc70 shown) in GALV injected tumours. Murine hsp70 was not induced, demonstrating that the heat shock expression is derived from the human tumour cells and not from mouse-derived cells. In addition, message of the human MICB molecule 25, 26 was induced by GALV expression within the tumour cells. MICB has recently been described as a receptor for both NK cells and ␥␦ T cells which is stress induced and which may regulate protective responses against tumour cells by certain subsets of immune cells. 25, 26 The combination of GALV, heat shock and MICB expression by tumour cells suggests that GALV FMG-mediated cell killing activates a potent stress response in the target cells which would be expected to be highly immunostimulatory in immunocompetent animals. 5, 6 In support of this hypothesis, we also observed the induction of murine (but not human) IFN-␥ in GALVtreated tumours (Figure 5) , consistent with the induction of an immune-mediated response to Lenti-GALV injected tumours. Even though these experiments were performed in immunodeficient mice, these data show that we cannot rule out the participation of some immunebased reactivity as a component to the efficacy of the Lenti-GALV treatment of tumours in Figure 3 . This immune stimulatory effect is not, however, a result of the lentiviral vector itself since none of the immune molecules were seen to be induced in tumours injected with similar viral loads of Lenti-␤-Gal.
Discussion
The GALV FMG is a C-terminally truncated form of the GALV, C-type retroviral envelope with the potential to be very potent for cancer gene therapy. 2 However, its cytotoxicity means that human producer cell lines start to be killed rapidly after transfection of the vector genome. Whilst we are in the process of developing strategies to control GALV FMG expression, 17 including the use of inducible promoters, 18 in general, adenoviral producer cell lines are rapidly killed before high levels of vector can be produced. Therefore, we compared the utility of C-type and lentiviral vectors for delivery of the GALV FMG for anti-cancer gene therapy. Although C-type retroviruses have been used previously, the therapeutic potential of lentiviral vectors in the context of cancer gene therapy is an area which has so far been largely untested. [27] [28] [29] We investigated the optimal strategies for packaging the GALV FMG cDNA into both C-type and lentiviral vectors. Expression of GALV FMG will rapidly fuse human cell lines so that stable human packaging cell lines cannot be generated. In contrast, murine cells lack the Pit-1 receptor so stable murine cell lines should be able to be cloned but the virus released by them would be sensitive to human complement inactivation in vivo. Finally, the GALV FMG is a truncated form of the wild-type GALV envelope protein which is itself a retroviral envelope capable of pseudotyping retroviral particles. Our data show that the GALV FMG alone is only poorly able to pseudotype Mo-MLV core particles packaging its own cDNA within a C-type vector. This suggests that the loss of the R peptide sequences relative to the wild-type GALV protein significantly affects the ability of the GALV FMG to incorporate into viral particles or, alternatively, to direct productive binding and fusion to target cells, as suggested by mutational analysis of the Mo-MLV envelope. 4 In addition, the GALV FMG significantly interferes with the ability of the MLV-A 4070A envelope in either murine (AM12) or human (FLY 13) producer cells to package high titres of C-type particles. We are testing the hypothesis that co-expression of the truncated GALV and the 4070A envelope leads to mixed heterotrimeric envelope complexes which are not competent for infection of target cells, despite reports of functional cooperation between different envelopes in another system. 21 In contrast, VSV-G was able to pseudotype Mo-MLV core particles containing the GALV FMG cDNA in a C-type vector but only to titres of 3 × 10 4 s.f.u./ml. When the GALV FMG cDNA was packaged in a lentiviral vector, the GALV FMG protein was able to pseudotype the HIV core particles only to low efficiency (Ͻ10 2 s.f.u./ml). However, VSV-G was able to pseudotype these particles with high efficiency to generate stocks of 4 × 10 6 s.f.u./ml. The protocol for production of lentiviral vectors used here 11, 12 is such that there is a much reduced conflict between the cytotoxic properties of the transgene and the requirements for viral packaging, unlike for the production of, for example, adenoviral vectors.
A potential advantage of C-type retroviral vectors is that they can only infect replicating cells 14 and could, therefore, confer a targeting advantage to tumour cells growing on a background of quiescent tissue. 30 Conversely, a potential disadvantage is that only a fraction of cells within human tumours are actually cycling at any given time. 8 Lentiviral vectors, in contrast, are capable of infecting both dividing and nondividing cells, [10] [11] [12] [13] although a recent report has suggested a cell cycle requirement for transduction of hepatocytes in vivo. 31 We confirmed that the Lenti-GALV, but not the lower titre C-type, stocks could infect both dividing and nondividing human tumour cells in vitro. This means that, although alternative methods of targeting of these vectors must be found to ensure accuracy of gene delivery/expression, 9 both the real titre (s.f.u./ml), and the effective titre in terms of the the potential pool of target tumour cells which they can productively infect, is likely to be higher for the Lenti-GALV vector than for its C-type counterpart.
Therefore, we tested the ability of the lentiviral stocks to treat established human tumour xenografts growing in nude mice. Three consecutive injections of 4 × 10 5 GALV FMG virus per tumour per day eradicated tumours of a mean diameter of 0.2 cm at the time of the first injection. Tumours injected with PBS or Lenti-␤-Gal virus continued to progress in vivo, although we did observe a slight retardation in the rate of growth of the Lenti-␤-Gal injected tumours. We are currently investigating the reasons for this effect. Nonetheless, this is the first demonstration, to our knowledge, of the use of a lentiviral vector to impact significantly on tumour growth in vivo.
The success of these experiments is almost certainly due to a combination of the viral titre and the potency of the GALV FMG. Each tumour received a total of about 1.2 × 10 6 syncytial forming virus particles into tumours which probably contained a minimum of 10 8 cells. The in vitro bystander assay of Figure 2 suggests a bystander killing ratio of about 1:100 cells by the GALV FMG delivered in a lentiviral vector, although whether this same level of direct bystander killing would also be produced in vivo is unclear. In this respect, several immune stimulatory molecules associated with a stress response, such as heat shock proteins 5 and the MICB NK cell receptor, 25, 26 were detected in GALV-treated tumours, which also induced expression of murine IFN-␥ at the tumour site. Therefore, there may indeed be some immune component associated with the antitumour effect of GALV FMG even in these immunocompromised animals which, although lacking in most functional T cells, still retain sets of immune effector cells such as NK cells.
Experiments are ongoing in which centrifuge-concentrated stocks of Lenti-GALV are injected into larger (70.5 cm) tumours; initial results show clear antitumoral activity of these viral stocks relative to the control LacZinjected tumours, although these larger tumours were not eradicated. In addition, ongoing experiments are demonstrating that the efficacy of the GALV FMG, in the context of the lentiviral vector, is similar in a variety of other human tumour lines including melanoma and colorectal cancer. Currently, we are also establishing experiments to examine these effects in immunocompetent animals, although these studies are made difficult since the GALV FMG does not fuse murine cells.
In summary, we have demonstrated the in vivo eradication of established human tumour xenografts using a fusogenic membrane glycoprotein and a lentiviral vector, a virus which has not previously been used for cancer gene therapy. The safety issues surrounding the use of lentiviral vectors are rapidly being addressed 13 and, in addition, inclusion of elements to target the vectors at the levels of the cell surface and transcriptional control is underway to prevent transduction of normal cells. Our results show that it is important to match the kinetics of viral vector production with the properties of specific therapeutic genes and that retroviral vectors still have Gene Therapy considerable potential for the delivery of gene therapies for cancer.
Materials and methods
FMG retroviral vectors
The GALV FMG cDNA was subcloned into the pBabePuro 32 vector backbone at the EcoR1 sites in the polylinker using standard techniques (details available on request). This C-type vector was packaged into viral particles by transfection of 5 g of plasmid DNA into the appropriate producer cell line (GP+envAM12; 22 FLY13 23 or the 293INT cell line which stably expresses the Mo-MLV gag and pol genes but no envelope (a gift from F Loic-Cosset, INSERM U412, Unité de Virologie Humaine, Lyon, France). The GALV FMG cDNA was also subcloned into the pHRЈCMV-LacZ SIN 33 lentiviral vector by removing the ␤-Gal gene and replacing it with a BamH1-Xho1 cut GALV cDNA. Lentiviral vectors were packaged by transfection of the 293T cell line with 10 g of the vector plasmid along with 10 g of the plasmid pCMV-R8.91 encoding the HIV gag, pol, tat and rev genes and 5 g of the plasmid pMD.G encoding the VSV-G envelope protein. 11, 12 Transfections were carried in a 10-cm plate out using the Profection (calcium phosphate coprecipitation) method (Promega, Madison, WI, USA). Forty-eight to 72 h following transfection, cell supernatants were recovered, filtered through a 0.45-m filter and either used directly for infection or frozen at −80°C. Viral titres (s.f.u/ml) were determined by exposing exponentially growing target cells in the absence of polybrene to different dilutions of viral supernatants in serum-free medium for 4 h in 24-well plates. The infectious medium was then removed and cells were washed three times before being allowed to grow in normal growth medium for a further 48 h. At this stage, infected cultures were fixed and inspected for syncytia. Syncytia were scored positive if they contained more than four nuclei.
To investigate whether the titres of the GALV-expressing retroviruses is dependent upon the ability of the target cells to divide, HT1080 target cells were pre-incubated in normal medium or medium containing 5 g/ml of aphidicolin which blocks DNA synthesis and arrests cells in G1-S. Twenty-four hours later the cells were infected with viral stocks. Forty-eight hours later, target populations were fixed and the number of syncytia per random field were counted (10 fields examined per plate).
In vivo studies All procedures were approved by the Institutional Animal Care and Use Committee at the Mayo Foundation. To assess the efficacy of virus-mediated delivery of the GALV FMG cDNA to progressively growing human tumour xenografts, athymic nude mice were injected with 2 × 10 6 HT1080 tumour cells to establish subcutaneous tumours. When the mean tumour diameter in each group of mice (10 mice per group) reached 0.2 cm, tumours were injected with viral stocks or PBS in a total volume of 100 l per tumour, per day, for 3 consecutive days. Animals were examined daily, tumour sizes were measured and experiments were terminated when tumor size reached 1.0 cm × 1.0 cm.
Analysis of tumours following in vivo transduction with lentiviral vectors
Tumours injected 48 h previously and growing subcutaneously in immunodeficient mice were surgically excised and treated as follows. For rtPCR analysis tumours were snap-frozen and used subsequently for the production of RNA. For ␤-galactosidase expression, tumours were dispersed into several parts, washed three times in PBS and incubated in X-gal solution for 4 h at 37°C. In addition, frozen sections of tumours were fixed in 2% glutaraldehyde, washed three times in PBS and incubated in X-gal solution for 4 h at 37°C before being examined microscopically to estimate the efficiency of gene transduction. For histological analysis, tumours were mounted in paraffin, sectioned and stained with haematoxylin and eosin (H and E) or frozen sections were stained with crystal violet.
Analysis of gene expression from explanted tumour cells by reverse transcriptase polymerase chain reaction RNA was prepared from explanted tumours by mechanical homogenisation of the tumour followed by RNA extraction with the RNAEasy kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. RNA concentrations were measured and 1 g total cellular RNA was reverse transcribed in a 20 l volume using oligo-(dT) as a primer and Moloney murine leukaemia virus reverse transcriptase (Pharmacia LKB Biotechnology, Milton Keynes, UK). A cDNA equivalent of 1 ng RNA was amplified by the polymerase chain reaction using primers specific for the target genes (details of primers and PCR conditions for each gene are available on request). PCR was performed in a 50 l reaction mixture with 250 m of each dNTP, 100 nm of primers, 5 l of 10 × buffer (HT Biotechnology, Cambridge, UK) and 1 unit of super Taq DNA polymerase (HT Biotechnology Ltd) using 30 cycles. The reaction mix (25 l samples) was analysed by agarose gel electrophoresis (1%) in TAE buffer containing 0.2 g/ml ethidium bromide. In all experiments, a mock PCR (without added DNA) was performed to exclude contamination. To exclude carryover of genomic DNA during the RNA preparation step, controls were also carried out in which the reverse transcriptase enzyme was omitted.
